Jefferies Assumes, Upgrades Esperion Therapeutics (ESPR) to Buy; Sees 100% Upside
Tweet Send to a Friend
(Updated - February 24, 2023 9:20 AM EST)
Jefferies analyst Dennis Ding assumes coverage on Esperion Therapeutics (NASDAQ: ESPR) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Jefferies analyst Dennis Ding assumes coverage on Esperion Therapeutics (NASDAQ: ESPR) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
